What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the ...

A review indicates obesity may amplify pathophysiology in HFrEF rather than acting as a primary cause, though weight loss data remain inconclusive.

An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with HF across the ejection fraction (EF) spectrum.

Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA) has accepted ...

A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the classification and treatment of heart failure with mildly reduced ejection fraction ...